UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 2, 2011

Myriad Genetics, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-26642

320 Wakara Way

Salt Lake City, UT 84108

(Address of principal executive offices, including zip code)

(801) 584-3600

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

(e) On December 2, 2011, at our annual meeting of stockholders, our stockholders approved an amendment to our 2010 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2010 Plan”), to increase the number of shares of common stock available for grant of awards under the 2010 Plan by an additional 3,500,000 shares. A description of the material features the 2010 Plan and related matters are set forth in our definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 11, 2011, under the heading “Proposal 2: Increase in the aggregate number of shares available for grant under our 2010 Employee, Director and Consultant Equity Incentive Plan,” and is incorporated herein by reference. Such description is qualified in its entirety by reference to the actual terms of the 2010 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

(a) On December 2, 2011, we held our annual meeting of stockholders. Of the 84,548,930 shares of common stock issued and outstanding and eligible to vote as of the record date of October 3, 2011, a quorum of 75,953,590 shares, or approximately 89.83 % of the eligible shares, was present in person or represented by proxy.

(b) At our annual meeting of stockholders, the following proposals were approved by our stockholders:

The final voting results on these matters were as follows:

(d) Consistent with the Board of Directors’ recommendation in the proxy statement and the shareholder votes at the annual meeting, the Board of Directors has determined to hold a non-binding, advisory vote on the compensation of our named executive officers each year until the next required vote on the frequency of such advisory vote. The next shareholder vote on the frequency of such advisory vote currently is expected to be held at our 2017 annual meeting of stockholders.

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX